Home Newsfeeds Wolfe Research Downgrades T-Mobile US to Peer Perform

Wolfe Research Downgrades T-Mobile US to Peer Perform

Wolfe Research analyst Peter Supino downgrades T-Mobile US (NASDAQ:TMUS) from Outperform to Peer Perform.

byBenzinga Newsdesk

January 3, 2023

1 minute read

Wolfe Research analyst Peter Supino downgrades T-Mobile US (NASDAQ:TMUS) from Outperform to Peer Perform.

Allogene Therapeutics Presents Preclinical Data On A Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 At The Society For Immunotherapy Of Cancer Annual Meeting

By Benzinga Newsdesk

November 3, 12:05 PM

Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic CancersSOUTH SAN

ALLO

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach To Treatment Of Uncontrolled Or Resistant Hypertension With Lorundrostat Data At AHA Scientific Sessions 2023

By Benzinga Newsdesk

November 11, 4:04 PM

– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone – – Excess aldosterone in patients

MLYS

Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)

By Benzinga Newsdesk

September 27, 7:05 AM

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced that its study

CANF